Pulsenmore Ltd. (PLSM)

The stock is currently trapped in a volatile consolidation phase following a massive 200% spike driven by the Ouma Health partnership news. While the headline business—FDA-authorized home ultrasound—is a compelling long-term narrative, the immediate price action shows significant weakness, trading well below its 52-week highs and struggling to reclaim key moving averages. The recent price history reveals a chaotic whipsaw pattern where gains were quickly erased, leaving the current price hovering near the bottom of its range. Fundamentally, the company is bleeding money with negative earnings, negative free cash flow conversion relative to revenue growth, and negative returns on both assets and equity. This suggests the market is deeply skeptical about the path to profitability despite the top-line growth. With no analyst coverage and no dividend to provide a floor, the investment case relies entirely on a successful execution of the new product rollout to turn the tide on profitability. Until the company demonstrates consistent earnings or a clear path to positive cash flow, the risk of further downside remains high, making this a hold for now rather than a buy.